An early-phase safety trial of an oncolytic virus delivered via injection has halted tumor progression in three pancreatic cancer patients, according to reporting from New Scientist. This phase 1 study, limited to a sample of three individuals with no control arm, demonstrates initial feasibility but leaves critical questions unanswered about durability, mechanisms, and scalability. Pancreatic cancer's dismal 5-year survival rate below 13% makes any signal noteworthy, yet the coverage underplays how prior oncolytic approaches, such as those using vaccinia or adenovirus vectors, have repeatedly faltered in larger cohorts due to immune clearance and stromal barriers unique to pancreatic tumors. The original piece misses connections to failed rapid-translation efforts like the 2010s surge in CAR-T hype for solid tumors, where small-n data fueled investment before phase 2 setbacks emerged. Related work in Clinical Cancer Research (2023) on engineered herpes viruses for pancreatic models highlights similar initial stasis in growth followed by resistance, while a 2024 Nature Reviews Cancer synthesis on virotherapy notes that only 2% of such trials advance past phase 1 without addressing tumor microenvironment heterogeneity. This result sparks valid debate on accelerating virotherapy but risks repeating patterns where preliminary safety data in n=3 cohorts drives premature commercialization without rigorous randomized controls.